Daily Stock Analysis, DXJ, DEXCOM INC, priceseries

DEXCOM INC. Daily Stock Analysis
Stock Information
Open
59.57
Close
58.43
High
59.57
Low
58.31
Previous Close
60.26
Daily Price Gain
-1.83
YTD High
65.37
YTD High Date
Jan 13, 2022
YTD Low
58.31
YTD Low Date
Mar 7, 2022
YTD Price Change
-4.36
YTD Gain
-6.94%
52 Week High
65.37
52 Week High Date
Jan 13, 2022
52 Week Low
56.88
52 Week Low Date
May 12, 2021
52 Week Price Change
0.80
52 Week Gain
1.39%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 11. 2017
46.88
Nov 9. 2017
51.82
43 Trading Days
10.54%
Link
LONG
Sep 4. 2019
44.00
Sep 24. 2019
46.90
14 Trading Days
6.58%
Link
Company Information
Stock Symbol
DXJ
Exchange
NASDAQ
Company URL
http://www.dexcom.com
Company Phone
8582000200
CEO
Kevin Ronald Sayer
Headquarters
California
Business Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001093557
About

Description

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.